Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Reata Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Reata Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Reata Pharmaceuticals, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Reata Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Reata Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Reata Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Reata Pharmaceuticals, Inc.'s pipeline products Reasons to buy - Evaluate Reata Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Reata Pharmaceuticals, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Reata Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Reata Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Reata Pharmaceuticals, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Reata Pharmaceuticals, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Reata Pharmaceuticals, Inc. Snapshot 5 Reata Pharmaceuticals, Inc. Overview 5 Key Information 5 Key Facts 5 Reata Pharmaceuticals, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Reata Pharmaceuticals, Inc. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Reata Pharmaceuticals, Inc. - Pipeline Products Glance 12 Reata Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Reata Pharmaceuticals, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 Reata Pharmaceuticals, Inc. - Drug Profiles 16 bardoxolone methyl 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 RTA-408 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 RTA-801 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Small Molecules Activating Nrf2 for Rheumatoid Arthritis 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecules to Activate Nrf2 for Duchenne Muscular Dystrophy 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecule Activating Nrf2 for Cystic Fibrosis 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecules to Activate CFTR for Cystic Fibrosis 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Reata Pharmaceuticals, Inc. - Pipeline Analysis 26 Reata Pharmaceuticals, Inc. - Pipeline Products by Target 26 Reata Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 27 Reata Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 28 Reata Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 29 Reata Pharmaceuticals, Inc. - Recent Pipeline Updates 30 Reata Pharmaceuticals, Inc. - Dormant Projects 32 Reata Pharmaceuticals, Inc. - Discontinued Pipeline Products 33 Discontinued Pipeline Product Profiles 33 bardoxolone methyl 33 Reata Pharmaceuticals, Inc. - Locations And Subsidiaries 34 Head Office 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 36 Disclaimer 36
List of Tables Reata Pharmaceuticals, Inc., Key Information 5 Reata Pharmaceuticals, Inc., Key Facts 5 Reata Pharmaceuticals, Inc. - Pipeline by Indication, 2014 7 Reata Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 8 Reata Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 9 Reata Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 10 Reata Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 11 Reata Pharmaceuticals, Inc. - Phase II, 2014 12 Reata Pharmaceuticals, Inc. - Phase I, 2014 13 Reata Pharmaceuticals, Inc. - Preclinical, 2014 14 Reata Pharmaceuticals, Inc. - Discovery, 2014 15 Reata Pharmaceuticals, Inc. - Pipeline by Target, 2014 26 Reata Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 27 Reata Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 28 Reata Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 29 Reata Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 30 Reata Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 32 Reata Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.